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ABSTRACT 
The combination of progressive cerebellar degeneration, hypogonadotropic 
hypogonadism and chorioretinal dystrophy defines the rare Boucher-Neuhäuser Syndrome 
(BNS), which has recently been linked to autosomal recessive mutations in the PNPLA6 gene 
in four index patients. Here we present two novel unrelated patients with BNS, where we 
identified four recessive PNPLA6 mutations (three of them novel) as the genetic cause, using 
a targeted high-throughput approach. This finding provides the first replication from 
independent families that BNS is caused by PNPLA6 and, moreover, highlights PNPLA6 as 
the major gene leading to BNS. Given the fact that the major gene causing BNS has thus now 
been identified, we summarize the spectrum of clinical presentations and phenotype evolution 
of BNS based on a systematic in-depth review of the literature of previously published cases 
(n=40). Both the two cases presented here and our review of the literature propose that the 
clinical presentation of BNS can be variable regarding both the age (ranging from 1 to 40 
years) and the clinical symptoms at onset (cerebellar ataxia in 38%; vision loss in 36%; 
delayed puberty in 26%). A substantial fraction of BNS cases may present with relatively 
selective atrophy of the superior and dorsal parts of the cerebellar vermis along with atrophy 
of the cerebellar hemispheres on MRI, while brainstem or cortical changes on MRI seem to be 
present only in small fractions. Also in the literature, no other major genetic causes of BNS 
other than PNPLA6 mutations were identified.  
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INTRODUCTION 
Degenerative cerebellar ataxia is frequently found in combination with additional non-
cerebellar deficits, giving rise to distinct syndromes. For example, it can occur in association 
with hypogonadotropic hypogonadism, as described in 1908 by Holmes [1] (Gordon Holmes 
syndrome). Similarly, cerebellar ataxia can be accompanied by retinal changes as e.g. in 
spino-cerebellar ataxia (SCA) type 7. However, the combined presence of deficits within all 
three domains – cerebellum, gonadic endocrinology and retina - is rarely found in the same 
patient. It was Boucher and Gibberd [2] who first reported the combination of slowly 
progressive ataxia, hypogonadotropic hypogonadism and chorioretinal degeneration in single 
families. Later, this syndrome was recognized as a specific disease entity known as Boucher-
Neuhäuser syndrome (BNS) (OMIM 215470) [1, 3, 4], named after the first authors of the 
first case descriptions. Very recently, recessive mutations in the PNPLA6 gene were reported 
in four families with the clinical phenotype of BNS, but also in one patient with Gordon 
Holmes syndrome and one with hereditary spastic paraparesis [5], suggesting that PNPLA6 
mutations cause BNS not as an isolated syndrome, but as a disease cluster on a continuous 
spectrum of neurodegenerative disorders (for an overview see [6]). Here we provide a detailed 
phenotype description of two novel index patients presenting with variable cerebellar ataxia, 
chorioretinal dystrophy and hypogonadotropic hypogonadism associated with recessive 
mutations in the PNPLA6 gene. Moreover, given the thereby now well-established link 
between BNS and PNPLA6 mutations, we review all published BNS cases focusing on the 
distribution, frequency and onset of both clinical (neurological, ophthalmological and 
endocrinological) findings and diagnostic testing including imaging, genetics and laboratory 
work-up. 
CASE DESCRIPTIONS 
Index patient #1  
 4 
The patient was referred to us at age 22 years with cerebellar ataxia and 
hypogonadotropic hypogonadism. At this time visual acuity was reportedly normal and a 
diagnosis of Gordon-Holmes syndrome was established. Testosterone substitution was 
started. Four years after the initial visit this patient was re-evaluated with newly recognized 
loss of vision, chorioretinal dystrophy and progressive ataxia of gait. 
First symptoms occurred in early childhood before age four years and included gait 
imbalance and frequent falls. Since then, gait slowly deteriorated. Blurred vision and 
“jumping eyes” were first noted around age 16 years but subjectively improved until age 25 
when he complained of reduced vision again. Speech became progressively slurred. The 
family history including one brother and two stepsiblings was unremarkable (see Fig. 1A for 
pedigree).  
 
/* Figure 1 about here */ 
 
The patient was of tall stature (186cm) and weighted 65kg, resulting in a body-mass-
index of 18.6 kg/m2. On clinical examination cerebellar loss of function was reflected both in 
ataxia of stance, gait and arm/leg movements, moderately dysarthric speech and ocular motor 
signs. This included downbeat nystagmus, horizontal gaze-evoked nystagmus, rebound 
nystagmus and saccadic smooth pursuit. Visual suppression of the vestibulo-ocular reflex 
(VOR) was severely impaired. At the same time, no clinical signs of peripheral audio-
vestibular dysfunction (normal head-impulse test, no head-shaking nystagmus) or peripheral 
neuropathy could be found. On clinical examination mild-to-moderate spasticity in the legs 
and increased ankle jerks bilaterally were noted, while plantar responses were flexor.  
Motor-evoked potentials showed delayed propagation along the corticospinal tracts to 
both legs and the left arm. MR-imaging obtained at age 27 years showed severe atrophy of the 
cranial and dorsal vermis (Fig. 2A). Cerebellar hemispheres and the pons were moderately 
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atrophic. In addition, new focal T2- and flair-hyperintensities were noted within the splenium 
corporis callosus and in the paramedian pons along the pyramidal tracts (Fig. 2B) and an 
empty sella syndrome was reported. 
 
/* Figure 2 about here */ 
 
Ophthalmologic examination at age 27 years revealed slightly reduced visual acuity 
(Snellen acuity: right eye 0.6, left eye 0.8) and paracentral scotoma in both eyes. Macular 
atrophy and atrophic changes in the retinal mid periphery in both eyes (Fig. 3), but normal 
anterior segment examination were found. Full-field electroretinogramm recorded according 
to ISCEV standard demonstrated reduced and delayed scotopic and photopic responses. 
 
/* Figure 3 about here */ 
 
Laboratory work-up showed normal creatine kinase and calcium levels and no 
evidence for hypersegmented neutrophils (as reported earlier for BNS patients [7-9]). Muscle 
biopsy was normal without signs of mitochondrial myopathy. Neuropsychological testing 
revealed reduced attention and cognitive flexibility and mild psychomotor slowing.  
Testosterone levels before substitution (05/2008) were below 0.5 pmol/l (normal range 
9.4 – 34.6 pmol/l), LH (02/2013) below 0.1 IE/l (normal range 1.7 – 8.6) and FSH (02/2013) 
0.8 IE/l (normal range 1.5-12.4). 
 
Index patient #2  
This 42-year-old patient (see Fig. 1A for pedigree) noticed a delayed puberty at age 13 
years, with endocrinological work-up leading to the diagnosis of hypogonadotropic 
hypogonadism.  He reported being a bit clumsy and worse in athletics since school age, yet 
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slowly progressive disturbance of gait, fine motor skills and speech started at age 32 years. At 
age 36 years, he noticed reduced vision in darkness. Visual acuity was normal (i.e. >1.0) in 
both eyes under daylight illumination. Fundus examination revealed chorioretinal 
degeneration with central retinal atrophy and pigment clumps. 
Neurological examinations starting at age 36 years confirmed a cerebellar ocular 
motor disorder (broken-up smooth pursuit, gaze-evoked horizontal nystagmus), cerebellar 
dysarthria, and a cerebellar trunk and limb ataxia (Scale for the Assessment and Rating of 
Ataxia [SARA] score: 9/40). There were no clinical or electrophysiological signs of upper 
motor neuron damage. Vibration sense tested at the medial malleolus was mildly and 
symmetrically reduced (4/8), corresponding to the nerve conduction findings of a mild 
axonal-demyelinating sensory-motor peripheral neuropathy. Brain MRI revealed marked 
cerebellar atrophy and an empty sella, yet no T2-hyperintensities. Neuropsychological testing 
demonstrated reduced attention and information speed processing, and reduced short-term and 
working memory. Also in this subject, we did not find evidence for hypersegmented 
neutrophils. 
 
Genetic investigation by targeted re-sequencing by a HaloPlex gene panel 
DNA of both subjects was investigated by a high coverage (>94% mean coverage) HaloPlex 
gene panel kit (Agilent, Santa Clara, CA, USA), which included 120 known ataxia genes (for 
details, see Supplement 1). Reads were mapped against the hg19 standard reference genome 
to detect SNPs, SNV, short deletions and insertions (SAMtools, IGV). We then filtered for 
non-synonymous homozygous or compound heterozygous truncating variants in any of the 
120 ataxia genes (frame-shift, insertions, deletions, and stop mutations) with low frequency in 
public databases (minor allele frequency in dbSNP137, NHLBI ESP6500 and the 
1000Genomes project (Annovar) < 0.5%). This filtering identified two recessive variants in 
both subjects only in the PNPLA6 gene, but not on any other of the 120 ataxia genes. Subject 
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#1 carried a stopgain (c.T288G; p.Y96X) and a missense (c.C865G; p.R289G) PNPLA6 
mutation, subject #2 carried a splicing (c.343-2A>T) and a missense mutation (c.C4075T; 
p.R1359W) in PNPLA6 (see Fig. 1B). All four mutations are either absent (3 of 4) or 
extremely rare (1 of 4) in large-scale control databases (see Table 1). Two of the mutations 
were missense mutations, predicted to be damaging by at least two in silico prediction 
programs; the other two mutations lead to truncating effects (see Table 1). Three of the four 
mutations are novel. Testing of all relatives available (the two fathers have already died; the 
sibling from index patient #1 was not available for genetic testing; see Figure 1A) showed 
that both mothers carried one of the respective heterozygous PNPLA6 variants identified in 
the respective index patient (mother index #1: c.C865G; mother index #2: c.343-2A>T), 
suggesting that the respective second PNPLA6 variant identified in each of the two index 
patients is not on the same allele (Figure 1A). Moreover, they show that the healthy sibling 
from family index #2 did not carry any of the PNPLA6 variants, thus adding further support 
for their pathogenicity. 
 
/* Table 1 about here */ 
Review of literature 
We performed a MEDLINE search using the search string “(boucher neuhauser 
syndrome) OR (ataxia AND hypogonadotropic hypogonadism AND retina*)”. Identified 
publications were screened for cases that fulfilled the criteria for BNS, i.e. that reported on 
patients presenting with (spino)cerebellar ataxia, hypogonadotropic hypogonadism and 
(chorio-) retinal abnormalities. If information about one or several of the core clinical findings 
in BNS was missing or was unclear, cases were not included. In addition, selected papers 
were screened for further references reporting on BNS cases. We identified 21 publications 
reporting a total of 40 patients that met our inclusion criteria. Key findings of the cases 
identified in the literature and of our own two index cases (i.e., of a total of 42 cases) are  8 
summarized below and in tables 2 and 3. For a more detailed description of all cases, see 
online supplement 2.  
Gender amongst the 42 cases (including both the 40 cases from the literature and our 
own two cases) was equally distributed (19 females, 23 males) and consanguinity was present 
in 13 of 28 cases if specified. In the majority of those cases the parents of the affected patients 
were second cousins (see Table 2 for details). Genetic testing was performed in 19 cases. An 
autosomal recessive mutation in the PNPLA6 gene was reported in nine cases from four 
families with the phenotype of BNS [5] and in the two index cases reported here. In a single 
case a 5.5kb mitochondrial DNA (mtDNA) single deletion and mitochondrial respiratory 
chain complex I deficiency was identified [10]. In the remaining seven cases screening for 
various spinocerebellar ataxias (SCA), dentatorubro-palloluysian atrophy (DRPLA), 
Friedreich ataxia and mtDNA mutations was negative.  
 
/* Table 2 about here */ 
 
Neurological findings included cerebellar ataxia (being present in all cases by 
definition), dysarthria (29/31 cases reported), pyramidal tract signs (confirmed in 13/31 
patients tested), peripheral neuropathy (confirmed in 6/26 patients assessed) and cognitive 
dysfunction (confirmed in 15/27 patients assessed, including mild cognitive impairment 
(MCI) in six cases (all from [5]), impaired intelligence in seven cases and reduced attention / 
cognitive flexibility in two cases). Ocular motor abnormalities were reported in 29/32 patients 
assessed. Most frequently horizontal gaze-evoked nystagmus (22/32), saccadic smooth pursuit 
eye movements (SPEM; 14/32), spontaneous vertical nystagmus (7/32; direction of fast phase 
specified in two cases only, reporting downbeat) and “nystagmus” without any further 
specification (6/32) were described.  
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Ophthalmological findings included chorioretinal degeneration, being reported in all 
but one case, in which BNS was genetically confirmed [5]. Visual acuity ranged from normal 
to bilateral blindness (see table 2). Visual field defects were present in 13/22 patients tested. 
Color vision was impaired in 6/11 patients evaluated. Abnormal retinal function was 
documented by electroretinogram (ERG) in 15/16 cases.  
Most often, ataxia or vision loss was the first symptom (in 38% and 36%, 
respectively), while delayed puberty was noted less frequently (26%) (Table 2). Age of onset 
varied: the first symptoms occurred between age 1 to 40 years (mean=14.0, 1SD=10.5 years), 
ataxia between age 4-40 years (mean=18.8, 1SD=11.2 years) and visual disturbances between 
age 1-48 years (mean=19.1, 1SD=14.3 years). 
Brain imaging identified “cerebellar atrophy” in 34/35 cases with more detailed 
descriptions of the pattern of cerebellar atrophy available only for some of the reported 
patients. This included atrophy of the cerebellar hemispheres (n=10) and / or atrophy of the 
cerebellar vermis (n=13). More pronounced atrophy of the superior and dorsal vermal lobules 
(I to VII) with caudal lobules (VIII, IX and X) being relatively spared was observed in 7/13 
cases with reported vermal atrophy. Brainstem atrophy, brainstem T2-hyperintensities and 
cerebral atrophy were noted infrequently (see Table 2 for details).  
All patients presented with hormonal changes of hypogonadotropic hypogonadism 
(usually low testosterone, FSH and LH values reported) or amenorrhea (primary in 17/18 
cases reported). Eleven out of 42 patients had a short stature. Laboratory abnormalities 
included hypersegmented neutrophils (n=7) and hypercalciuric hypocalcaemia (in two 
siblings [11]). Results from lumbar puncture were available in two cases only (being 
reportedly normal). Muscle biopsy, reported in 5 patients, did not reveal any abnormalities.  
DISCUSSION 
Using a novel targeted re-sequencing high-throughput approach, we identified four 
recessive PNPLA6 mutations (three of them being novel) as the cause of the disease in two  10 
previously unreported BNS index cases. This finding provides the first replication from 
independent families that BNS is indeed caused by PNPLA6 [5] and, in addition, that BNS 
can also present as a „spastic BNS“ (pyramidal tract damage in index patient #1). The latter 
finding adds support to the previous notion that PNPLA6 mutations do not cause BNS as an 
isolated syndrome, but as a disease cluster on a continuous spectrum of neurodegenerative 
disorders extending from pure ataxia or hereditary spastic paraplegia to severe multisystemic 
syndromes like e.g. BNS additionally complicated by spasticity (for an overview see [6]). 
Moreover, our finding highlights PNPLA6 as the major gene leading to BNS: the first 
series identified PNPLA6 mutations in four out of six BNS families [5], and we observed 
PNPLA6 mutations in two out of two BNS families. These findings suggest that PNPLA6, 
which encodes neuropathy target esterase (NTE), a lysophospholipase that maintains 
intracellular phospholipid homeostasis by converting lysophosphatidylcholine (LPC) to 
glycerophosphocholine [12], should be primarily screened in subjects with BNS. Moreover, 
they lead to the hypothesis that a substantial fraction of the genetically still undefined BNS 
cases from the literature as reviewed here will carry PNPLA6 mutations. Our findings  
demonstrate for the first time that even mutations leading to the “full-blown” BNS phenotype 
are not restricted to the phospholipid esterase (EST) or cyclic nucleotide binding-homology 
(CNB) domains of the gene, but can be found across the whole gene (Fig. 1B). Thus, 
screening of PNPLA6 in still undefined BNS patients will require sequencing the full gene, 
rather than just the main established functional domains.  
Clinically, BNS can be distinguished from the Gordon Holmes syndrome [13] and the 
Woodhouse Sakati syndrome [14] by the presence of chorioretinal dystrophy and absent / 
mild cognitive dysfunction. For the differential diagnosis of BNS, mitochondrial disorders 
must be considered as they may present with cerebellar ataxia and progressive retinal 
degeneration [15] or with cerebellar ataxia and hypogonadotropic hypogonadism [16, 17]. 
On the level of single families, a possible autosomal-recessive trait of inheritance 
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(several affected siblings, no genetic testing [2, 7, 18], has been proposed in the past – often 
in association with parental consanguinity (e.g. [7, 18]). With recent advances in genetic 
testing in BNS, resulting in the identification of PNPLA6 as the major target gene and an 
autosomal recessive pattern, this originally clinically defined entity is becoming part of a 
larger spectrum of neurodegenerative disorders including Gordon Holmes syndrome, 
hereditary spastic paraparesis, and spastic ataxia [5].  
Both the case presented here and the reviewed cases in the literature suggest that the 
phenotype can be variable regarding the age and the symptoms at disease onset. Albeit BNS is 
rare, this finding prompts both pediatric and adult caregivers to look for additional key 
features of BNS if one of the core symptoms is present, especially if the family history for 
neurological or ophthalmological disorders is positive or consanguinity is the case. Early 
detection of the syndrome may accelerate hormonal substitution, the prescription of visual 
aids, balance and speech therapy, and adequate genetic and psychosocial counselling.  
As shown by our review, visual loss is severe in about 20% of the patients. Amongst 
neurological findings dysarthria accompanies cerebellar ataxia in almost all cases and a 
substantial fraction of BNS patients presents with pyramidal tract findings, underlining the 
spinocerebellar character of this disease and the often “spastic BNS” presentation [5, 7]. 
Ocular motor abnormalities can be observed in almost all cases, with deficient cerebellar 
gaze-holding, saccadic smooth pursuit and vertical (most likely downbeating) nystagmus 
constituting the core diagnostic findings. Moderate cognitive impairment (see e.g. cases from 
[7, 18]) and peripheral polyneuropathy may be present in substantial fractions as well. Pes 
cavus [2, 4, 19] was described by several authors and movement disorders such as focal 
(craniocervical) dystonia and chorea may develop in BNS [20]. Hypersegmented neutrophils 
are an inconstant finding in BNS, and so far none of the genetically confirmed cases showed 
these hematological changes. Thus, it does not seem to serve as a reliable blood biomarker for 
underlying PNPLA6 disease. 
 12 
As suggested by the reviewed cases and our index patient #1, a significant proportion 
of BNS cases may present with relatively selective atrophy of the superior and dorsal parts of 
the vermis along with atrophy of the cerebellar hemispheres, while brainstem or cortical 
changes seem to be present only in small fractions. However, this pattern is likely not specific 
for BNS, as it may be observed also in patients with degenerative cerebellar ataxia without 
chorioretinal disease or hypogonadism. It will be of interest whether the pontine T2 
hyperintensities observed in index patient #1 can be identified in future PNPLA6-confirmed 
BNS subjects as well. In the literature, infratentorial T2-hyperintensities were noted only in a 
single case (which awaits genetic confirmation) [21], but might have been overlooked in 
previous cases. Although such hyperintensities are certainly not specific to BNS/PNPLA6-
disease, they are not common features in other hereditary ataxias. Moreover, they might 
provide a link to the pathophysiology of PNPLA6-caused BNS, which is increasingly shown 
to be related to disorders in phospholipid metabolism [5, 12, 22]. 
To summarize, albeit defined clinically by the combination of (spino)cerebellar  
ataxia, chorioretinal degeneration and hypogonadotropic hypogonadism, the Boucher 
Neuhäuser Syndrome may vary considerably in disease onset, clinical presentation and 
progression. Thus, we recommend a thorough assessment for ophthalmological, neurological 
and endocrinological changes in patients presenting with one of the key features. With 
PNPLA6 likely causing the large majority of BNS cases, future identification of the 
underlying gene defect will be facilitated. Moreover, future research clarifying the 
relationship of BNS with other ataxia syndromes likely will be accelerated and detailed 
phenotype characterization and phenotype-genotype correlation will be possible.  
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FIGURES 
 
Figure 1 
Genetic investigations in the two index patients. Panel A: pedigrees of the two index 
families and segregation of the PNPLA6 variants. In both families, the affected subjects were 
simplex cases without affected parents and without consanguinity. Each of the two mothers 
carried only one PNPLA6 variant, suggesting that the respective second PNPLA6 variant 
identified in each of the two index patients is not on the same allele. Arrows: subjects 
available for genetic testing of segregation of the respective PNPLA6 variants. Panel B: 
Schematic of the exon-intron arrangement of PNPLA6 (NCBI reference NM_001166111.1), with 
positions of the mutations reported here and previously (updated version of the schematic presented in 
[5]). Exons are indicated as black boxes. CNB1/2 and the phospholipid esterase functional domains 
are indicated by purple and orange boxes, respectively. The mutations are indicated and color-coded 
by the phenotype observed.  
Figure 2 
Structural brain imaging of index case #1: On sagittal T2-weighted MR-imaging (panel A) 
severe atrophy of the cranial and dorsal lobules (I–VII) of the cerebellar vermis can be seen, 
whereas the caudal vermal lobuli (VIII–X) are relatively intact. On axial fluid-attenuated 
inversion recovery (FLAIR) images (panel B) and on T2-weighted sequences (not shown) 
focal hyperintensities along the pyramidal tracts (referred to by the white arrows) at the level 
of the paramedian pons can be depicted. 
 
Figure 3 
Ophthalmological findings of index case #1: Color fundus photography of the right and left 
eye illustrating retinal atrophy. Visual field examination (bottom) shows paracentral scotoma 
but normal peripheral field response.   14 
TABLES 
 
Table 1: PNPLA6 Mutations identified in this study 
 
AA, amino acid change, Mutation Taster score between 0 and 1; the higher it is, the higher is the probability of pathogenicity. SIFT, Sorting Tolerant 
From Intolerant. SIFT scores < 0,05 represents damaging effect. PolyPhen2; Range: 0-1, higher scores indicate a higher likelihood of pathogenicity. 
Interpretation: benign (0-0.452), possibly damaging (0.453-0.956), probably damaging (0.957-1). All positions refer to transcript NM_001166111. 
ESP6500, minor allele frequency (MAF) in NHLBI ESP6500, 1000g, count in the 1000 genome project. 
 
Region Exon chr. Position 
Nucleic acid 
change AA Change Variant type Status 
variant 
status 
Mutation 
Taster ljb2 SIFT ljb2 
Polyphen2 hdiv 
ljb2 
esp6500 
count 
1000g 
count  
exonic Ex4 chr19:7601105 c.T288G p.Y96X stopgain Hetero new 1 1 - - - 
exonic Ex9 chr19:7605851 c.C865G p.R289G missense Hetero new 0,947 0,03 0,088 - - 
splicing Ex5 chr19:7601333 c.343-2A>T - - Hetero known - - - 0,0001 - 
exonic Ex34 chr19:7626395 c.C4075T p.R1359W missense Hetero new 0,2675 0 0,999 0,0002 - 
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Table 2: Prevalence of key findings in BNS 
 present absent not reported 
Epidemiological findings    
Consanguinity 13/42 (31%) 15/42 (36%) 14/42 (33%) 
First cousins 2/13 (15%)   
Second cousins 8/13 (62%)   
Not specified 3/13 (23%)   
Genetic defects * 12/42 (29%) 7/42 (17%) 23/42 (55%) 
    
First complaints †    
Cerebellar ataxia 16/42 (38%)   
Progressive visual loss 15/42 (36%)   
Delayed puberty 11/42 (26%)   
    
Neurological findings    
Ocular motor abnormalities 29/42 (69%) 3/42 (7%) 10/42 (24%) 
Horizontal gaze-evoked nystagmus 22/42 (52%)   
Vertical nystagmus ‡ 7/42 (17%)   
Saccadic smooth pursuit 14/42 (33%)   
Impaired saccades 3/42 (7%)   
„Nystagmus“ 6/42 (14%)   
Dysarthria 29/42 (69%) 2/42 (5%) 11/42 (26%) 
Pyramidal tract signs § 13/42 (31%) 18/42 (43%) 11/42 (26%) 
Peripheral neuropathy II 6/42 (14%) 20/42 (48%) 16/42 (38%) 
Cognitive dysfunction 15/42 (36%) 12/42 (29%) 15/42 (36%) 
    
Ophthalmological findings    
Visual loss ¶ 26/42 (62%) 4/42 (10%) 12/42 (29%) 
Visual acuity ≥0.5 on better eye 7/23 (30%)   
Visual acuity ≥0.1 & <0.5 on better eye 11/23 (48%)   
Visual acuity <0.1 on better eye 5/23 (22%)   
Chorioretinal dystrophy #  41/42 (98%) 1/42 (2%) 0/42 (0%) 
    
Brain imaging ** 35/42 (83%) 0/42 (0%) 7/42 (17%) 
Cerebellum    
Any kind of cerebellar atrophy 34/35 (97%)   
Atrophy of cerebellar hemispheres 10/35 (29%)   
Atrophy of cerebellar vermis 13/35 (37%)   
Brainstem    
Brainstem atrophy 5/35 (14%)   
Brainstem T2-hyperintensities 2/35 (6%)   
Cerebrum    
Cerebral atrophy 2/35 (6%)   
Cerebral T2-hyperintensities 5/35 (14%)   
 
* In addition to our two index cases, one report found 9 cases with heterozygote mutations in the PNPLA6 gene 
[5] and one report found a 5.5kb mtDNA single deletion in one case [10]. Negative testing included SCA 1 
(n=6), 2 (n=6), 3 (n=5), 6 (n=3), 7 (n=2), 8 (n=2), 12 (n=1, 17 n=1), DRPLA (n=2), mtDNA (n=4), FRDA (n=3) 
 
† In one case first complaints developed at the same time in two domains (delayed puberty and progressive 
visual loss, reported by Synofzik et al. [5]). In one case first complaints were not reported, total number of 
events is therefore n=42.  
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 ‡ In two cases the fast phase of vertical nystagmus was specified as downbeat nystagmus  
 
§ This includes spastic muscle tone (n=5), increased deep tendon reflexes (DTR) (n=5) and extensor plantar 
response (n=6). Note that more than one complaint was found in part of the affected patients. 
 
II For a diagnosis of PNP clinical findings as reduced / absent DTRs and / or sensory deficits had to be 
confirmed either by abnormal ENMG (n=2 with axonal PNP, n=1 with demyelinating PNP, n=1 with mixed 
axonal-demyelinating PNP) or pathological nerve biopsy (n=2 with axonal degeneration). A normal ENMG 
exam was reported in 11 cases. In 8 cases (all from [5]) only reduced or absent patellar tendon reflex and 
Achilles tendon reflex were reported, but no information was available regarding sensory loss, ENMG or nerve 
biopsy. Therefore these cases were rate das having insufficient information to confirm / dismiss a diagnosis of 
PNP. 
 
¶ Visual loss was defined as corrected visual acuity of less than 1.0 on both eyes. Only patients included with 
specific visual acuity values or rating as finger counting, hand movements, light perception or blindness (n=23). 
 
# Different morphological descriptions, including (chorio-) retinal dystrophy / atrophy / degeneration, 
maculopathy, macular atrophy, chorio-retinopathy, (atrophic) pigmentary retinopathy, RPE (and choriocapillary) 
atrophy, peripapillary atrophy, dystrophic retinal pigment epithelium. 
 
** From 35 cases with imaging, 30 received an MRI and 5 a CT.  
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